Background:Acute coronary syndrome (ACS) continues to be a leading cause of morbidity and mortality worldwide. Limited data on galectin-3 and pentraxin-3 are found as biomarkers in the ACS population. The objective of this study was to determine the variables that are most affected by high concentrations of pentraxin-3 (PTX-3) and galectin-3 (GAL-3), and the influence they have on outcomes of all-cause mortality in patients with ACS. Patients & Methods:One hundred and fifty patients with ST elevation myocardial infarction (STEMI) were included with 30 healthy subjects served as controls. Blood samples were drawn beforeprimary percutaneous coronary intervention (PCI) and after 12 and 48 hours. Critical changes in Troponine I as well as in PTX-3, GAL-3, lipid profile, CRP, RBS and cardiac enzymes markers were examined. Results:Highly significant time dependent increase in serum PTX-3 and Gal-3 was observed among acute STEMI patients when compared to controls. Troponin I, PXT-3, and GAL-3 showed high sensitivity and specificity in the prediction of Acute STEMI. Sensitivities of Troponin I, PXT-3, and GAL-3 were 96%, 90% and 94% respectively, while specificities were 85%, 85% and 85% respectively. Moreover, significant increase in Troponin I, LDH, AST, CK-total, CK-MB, CRP, RBS and lipid profile were observed among the acute STEMI patients as compared to controls. Conclusion:We can conclude that both PTX-3 and GAL-3 could be excellent biomarkers of CVDACS. PTX-3 and GAL-3 plasma levels rise rapidly in acute myocardial infarction, reflecting the extent of tissue damage and predicting the risk of mortality